<DOC>
	<DOCNO>NCT02581501</DOCNO>
	<brief_summary>GAX represent novel approach development cancer chemotherapy agent pancreatic cancer base upon extensive laboratory investigation induction apoptosis pancreatic carcinoma cell .</brief_summary>
	<brief_title>Prospective Phase I Study GAX Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>It investigators expectation combination induce apoptotic pathway downstream biochemical mechanism resistance synergistically induce pathway apoptosis non-p53 dependent , previously explore chemotherapy trial cancer . ABRAXANE® novel induces apoptosis degree mutant wt p53 cancer . Mutant p53 tumor occur 80-90 % PC mutant p53 think one major mechanism drug resistance . Furthermore , investigator start Xeloda gemcitabine slightly low dose initial GTX study . This investigator find efficacy maintain slightly low dos side effect minimize . The reason GTX work low dos , well high dos , synergy drug . Drug regimens synergistic maintain antitumor effect dose low non-synergistic regimen , must maintain dose intensity achieve anti-tumor effect . RECIST 1.1 criterion utilized judging response , progression stable disease . Overall assessment data intention treat analysis ( ITT ) .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma pancreas metastatic distant site . ( Stage IV ) . 2 . Must lesion reproducibly measurable CT MRI scan per Recist 1.1 criterion 3 . Prior radiation surgery allow ( except Target lesion ) GAX treatment : &gt; 3 week since major surgery 1 . Bilirubin &lt; 1.5 mg/dL 2 . Patients must adequate liver function : AST ALT &lt; 2.5 X upper limit normal , alkaline phosphatase &lt; 2.5 X upper limit normal , unless bone metastasis present ( &lt; 5 X upper limit normal ) absence liver metastasis . 3 . Patients must adequate bone marrow function : Platelets &gt; 100,000 , Hemoglobin &gt; 9.0g/dL ANC &gt; 1,500 4 . Patients must adequate renal function : creatinine &lt; 1.5 mg/dL recommend 4 . Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment . 5 . Patients must &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE ) 6 . Clinical Parameters Life expectancy &gt; three month Age ≥ 18 year ≤ 75 year Performance status 01 ( ECOG ) Preexisting Peripheral Neuropathy ( sensory ) must ˂ grade 2 Able tolerate oral medication 7 . Informed Consent : Each patient must completely aware nature his/her disease process must willingly give consent inform experimental nature therapy , alternative , potential benefit , sideeffects , risk , discomfort . 8 . PT/PTT within normal therapeutic limit determine investigator . All subject Xeloda , use warfarin exclusionary . 1 . Neuroendocrine cancer rule histology immunohistochemical stain specimen . Mixed histology , pancreatic neuroendocrine adenocarcinoma tumor , also exclude . 2 . Prior chemotherapy allow , long less equal two component GAX use previously treatment : include gemcitabine , capecitabine , 5FU , ABRAXANE® . 3 . Hypersensitivity : Patients history severe hypersensitivity reaction taxanes drug formulate polysorbate 80 , drug GAX regimen exclude . 4 . Serious medical psychiatric illness prevent informed consent intensive treatment ( e.g . serious infection ) would opinion investigator , increase risk serious neutropenic complication . 5 . Serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise subject 's safety study data integrity . 6 . Patients compromise immune system increase risk toxicity lethal infection treat marrowsuppressive therapy . 7 . Serious cardiovascular thromboembolic disease , include : congestive heart failure NYHA class III great ; unstable angina new onset angina ( start within three month screen protocol ) , myocardial infarction within past 3 month ( prior screening ) ; serious cardiac arrhythmia require therapy ; cerebrovascular accident include transient ischemic attack within past 3 month ( prior screening ) . 8 . Serious nonhealing wound , ulcer , bone fracture . 9 . Evidence history bleed diathesis . 10 . Major surgery , open biopsy significant traumatic injury within 3 week receive first study drug . 11 . Use cytochrome P450 enzyme induce drug : antiepileptic drug ( phenytoin , carbamazepine , phenobarbital , Keppra ) , St. John 's Wort rifampin ( rifampicin ) . 12 . Prior malignancy last 2 year curatively treat carcinoma insitu site , nonmelanoma skin cancer , Stage I breast and/or bladder cancer ( situ ) , early stage prostate cancer Stage I II , curatively treat surgery and/or radiation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Xeloda</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Phase I</keyword>
	<keyword>5-FU</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>NAB-Paclitaxel</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>